Current stock page

Financial Data

TGTX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TGTXTG Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$64.51−$0.05 (−0.08%)

Latest quote

  • Momentum
    93
  • Value
    65
  • Quality
    69
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$259.94M$240.34M$204.92M$192.57M$161.71M$141.15M$120.86M$108.19M
Gross Profit$217.86M$199.14M$171.41M$154.43M$133.55M$122.21M$105.32M$92.79M
Operating Income$85.9M$21.67M$34.8M$50.49M$29.37M$34.84M$8.62M$29.95M
Net Income$55.46M$7.78M$19.78M$23.04M$390.9M$28.19M$5.06M$23.33M
EPS$0.39$0.05$0.14$0.16$2.69$0.19$0.03$0.16
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$45.23M$39.26M-$17.89M$19.66M-$23.15M$7.44M-$28.72M-$25.64M
Capital Expenditure-$282K-$293K-$51K-$67K-$80K-$42K-$25K-$21K
Free Cash Flow$44.95M$38.97M-$17.95M$19.59M-$23.23M$7.39M-$28.74M-$25.66M
Net Cash Provided By Operating Activities$45.23M$39.26M-$17.89M$19.66M-$23.15M$7.44M-$28.72M-$25.64M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.59B$1.64B$1.53B$1.06B$1.03B$702.61M$656.69M$577.69M
Total Debt$754.37M$754.44M$753.56M$260.73M$253.72M$253.72M$253.71M$253.72M
Cash And Cash Equivalents$429.38M$482.58M$442.21M$79.15M$74.08M$129.13M$132.14M$179.89M
Total Liabilities$1.02B$1.04B$945.71M$415.23M$417.81M$426.18M$419.4M$355.33M
Total Stockholders Equity$572.13M$604.08M$583.13M$648.02M$607.22M$276.43M$237.29M$222.36M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio93.1817.7714.5410.7212.2571.82139.86235.88
P/B ratio17.2712.9911.527.49.0315.7123.0824.8
P/S ratio10.12———————
Debt To Equity1.321.251.290.40.420.921.071.14
Free Cash Flow Yield0.87%-0.01%-0.21%-0.52%-1.28%-1.36%-1.12%-0.74%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio93.1817.7714.5410.7212.2571.82139.86235.88
P/B ratio17.2712.9911.527.49.0315.7123.0824.8
P/S ratio10.12———————
Return On Equity18.54%73.08%79.21%69.01%73.69%21.87%16.50%10.52%
Debt To Equity1.321.251.290.40.420.921.071.14

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe86.6x
Pb15.87x
Revenue Growth Yoy60.74%
EPS Growth Yoy-85.50%
Gross Margin82.74%
Operating Margin21.48%
ROE17.62%
ROIC10.26%
Debt To Equity1.32
FCF Yield0.88%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$64.51
Volume1.1M
RSI (14)65.39
MACD2.53
MACD signal1.87
MACD histogram0.65
ADX (14)24.02
SMA (50)$56.69
SMA (200)$45.38
ATR (14)$3.09
Historical volatility (annualized)43.31%
Volume (20-day average)2.1M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score63/100
Beta0.68
Annual volatility46.06%
Max Drawdown-21.83%
Sharpe Ratio1.74
VaR (95%, 1-day)-3.63%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TGTX Financial Data FAQ

What is TG Therapeutics, Inc.'s revenue?

TG Therapeutics, Inc.'s revenue is one of the core financial data points for TGTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is TG Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether TG Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TGTX's EPS?

TGTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is TG Therapeutics, Inc.'s net income?

TG Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does TG Therapeutics, Inc. generate?

Free cash flow shows how much cash TG Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does TG Therapeutics, Inc. have?

Cash and debt help frame TGTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.